Market Overview - The Shanghai Composite Index fell by 0.64% on January 13, with six industries experiencing gains, led by the oil and petrochemical sector (up 1.62%) and the pharmaceutical and biotechnology sector (up 1.21%) [1] - The defense and military industry and the electronics sector saw the largest declines, down 5.50% and 3.30% respectively [1] Capital Flow Analysis - The net outflow of capital from the two markets was 162.743 billion yuan, with only four industries seeing net inflows [1] - The pharmaceutical and biotechnology sector had the highest net inflow of capital at 4.348 billion yuan, followed by the oil and petrochemical sector with a net inflow of 586 million yuan [1] - The electronics industry experienced the largest net outflow, totaling 37.010 billion yuan, followed by the computer industry with a net outflow of 23.107 billion yuan [1] Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector rose by 1.21%, with a total of 478 stocks in the sector, of which 329 stocks increased in value and 16 stocks hit the daily limit [2] - A total of 256 stocks in the sector saw net capital inflows, with 21 stocks receiving over 100 million yuan in net inflows; leading was Mindray Medical with a net inflow of 372 million yuan [2] - The stocks with the highest net outflows included Hainan Haiyao, Huahai Pharmaceutical, and Sanbo Brain Science, with net outflows of 204 million yuan, 164 million yuan, and 153 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - Notable gainers included: - Mindray Medical: up 0.09% with a capital flow of 371.57 million yuan [3] - International Medical: up 9.96% with a capital flow of 290.33 million yuan [3] - Haiwang Biological: up 9.97% with a capital flow of 242.73 million yuan [3] - Boji Pharmaceutical: up 19.96% with a capital flow of 241.23 million yuan [3] - Erkang Pharmaceutical: up 19.95% with a capital flow of 237.43 million yuan [3] Top Losers in Pharmaceutical Sector - Notable losers included: - Hainan Haiyao: down 4.82% with a capital outflow of 203.78 million yuan [5] - Huahai Pharmaceutical: down 3.60% with a capital outflow of 163.67 million yuan [5] - Sanbo Brain Science: down 3.93% with a capital outflow of 153.22 million yuan [5] - Xiangrikui: down 5.49% with a capital outflow of 147.26 million yuan [5] - Luyan Pharmaceutical: down 3.74% with a capital outflow of 110.10 million yuan [5]

Core Insights - The approval of Zeshuo Pharmaceutical's injection of human thyroid-stimulating hormone beta (Zesuning) marks a significant milestone as it becomes China's first innovative product approved for precise assessment post-surgery for differentiated thyroid cancer [1][2] - The Chinese innovative drug industry is experiencing robust growth, with multiple new drugs receiving approval since the beginning of 2026, including innovative drugs from companies like Hengrui Medicine and BeiGene [1][2] - The National Medical Products Administration (NMPA) is enhancing support for innovative drugs, focusing on new mechanisms and targets, and aims to facilitate the "China first launch" of innovative drugs [3][4] Company Developments - Hengrui Medicine's innovative drug, the dual-specific antibody fusion protein Ruilafuzumab α injection, has been approved as the world's first anti-PD-L1/TGF-βRII dual-specificity antibody fusion protein for advanced gastric cancer [1][2] - BeiGene's innovative drug, Sotorasib tablets, has received conditional approval for treating chronic lymphocytic leukemia/small lymphocytic lymphoma and is the first and only BCL2 inhibitor approved for treating mantle cell lymphoma in China [2] - The approval of multiple innovative drugs reflects a significant increase in the number of innovative drugs approved in China, with 76 approved in 2025, surpassing the 48 approved in 2024 [2] Industry Trends - Approximately 20 major new drugs are expected to receive approval in 2026, covering various therapeutic areas such as oncology, infectious diseases, rare diseases, autoimmune diseases, and neurological disorders [3] - The Chinese innovative drug industry is transitioning from a follower to a competitor, with many domestic companies accelerating the development and market entry of groundbreaking innovative drugs [2][3] - The NMPA is implementing reforms to enhance the drug approval process, including the introduction of a data protection system for drug trials and a market exclusivity system for pediatric and rare disease medications [4][5] Policy Support - The NMPA is set to provide comprehensive support across the entire chain of communication, clinical trials, registration, and review processes for innovative drugs [4] - The new medical insurance directory has been implemented, facilitating the inclusion of innovative drugs in hospitals, which alleviates initial payment challenges for high-value innovative drugs [4] - The NMPA is also optimizing the review process for urgently needed foreign drugs, encouraging global simultaneous research and application in China [4][5]

Core Viewpoint - The article discusses the initiation of a Phase III clinical trial for HB0025, a drug developed by Huahai Pharmaceutical's subsidiary, Huatai, aimed at treating advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy [1][4]. Group 1: Clinical Trial Details - The clinical trial, registered under CTR20260016, is a randomized, double-blind, multi-center study named DUALIGHT-02, which will evaluate the efficacy and safety of HB0025 in comparison to pembrolizumab combined with chemotherapy [2][4]. - The trial aims to enroll 480 participants in China, with the primary endpoint being progression-free survival (PFS) assessed by blinded independent central review (BICR) according to RECIST v1.1 criteria [4]. - The drug HB0025 is an innovative PD-L1/VEGF dual-specific fusion protein designed to target both tumor immune evasion pathways and tumor angiogenesis pathways, providing a dual mechanism of action [4]. Group 2: Drug Development Status - HB0025 has reached Phase III clinical trials in China, while it is currently in Phase II globally for various cancers, including hepatocellular carcinoma and triple-negative breast cancer [5][9]. - The drug has shown promising results in earlier trials, with an objective response rate (ORR) of 83.3% in the squamous NSCLC cohort and 100% in the high PD-L1 expressing group, along with a disease control rate (DCR) of 95.8% [7]. - Huahai Pharmaceutical has invested approximately 326 million yuan in the development of HB0025 [9].

Core Viewpoint - The article emphasizes the importance of selecting the right sectors in the A-share market, particularly focusing on emerging industries supported by government policies, such as integrated circuits, new energy, and biomedicine, which are expected to yield significant returns in the coming year [1]. Group 1: Selection Logic - The ten selected stocks are based on three hard standards: policy support, performance certainty, and reasonable valuation [3]. - Policy support is derived from the Ministry of Industry and Information Technology's focus on emerging pillar industries, which will benefit from research subsidies and industrial support [3]. - Performance is guaranteed with expected revenue/net profit growth of at least 20% and a return on equity (ROE) of at least 15% by 2025, with data sourced from company annual reports [3]. - Valuation is considered reasonable if the price-to-earnings (PE) and price-to-book (PB) ratios are below industry averages or at historical lows, providing a safety margin [3]. Group 2: Potential Stocks Analysis - The ten companies span key sectors such as semiconductors, new energy, and biomedicine, each with solid growth logic supported by authoritative data [5]. - Notable companies include: - Northern Huachuang (002371): A leader in semiconductor equipment with a leading domestic market share and a PEG of 1.2 [5]. - China Great Wall (000066): A core player in the Xinchuang hardware sector with a historical low PE of approximately 28 times and strong asset integration expectations [5]. - Desheng Technology (002908): A small-cap stock benefiting from social security services and data rights, with high elasticity expected as policies accelerate in 2026 [5]. Group 3: Core Sector Opportunities - Three key sectors are highlighted for their concentrated policy benefits and strong growth certainty: - Semiconductors and domestic substitution: The Ministry of Industry and Information Technology is promoting industrial foundation reconstruction, benefiting companies like SMIC and Northern Huachuang [6]. - New energy (photovoltaics and energy storage): The national energy work conference aims for an additional 200 million kilowatts of wind and solar installations by 2026, with companies like Longi Green Energy and CATL positioned to benefit [6]. - Biomedicine and innovative drugs: As an emerging pillar industry, stable policies and accelerated overseas expansion are expected to benefit companies like Heng Rui Medicine and Huahai Pharmaceutical [6]. Group 4: Practical Guide for Investors - Investors are advised to utilize three practical methods to seize opportunities without falling into pitfalls: - Verify authoritative information by checking company annual reports on the Shanghai and Shenzhen Stock Exchanges to confirm performance and order status [8]. - Diversify investments by selecting 1-2 stocks from each of the semiconductor, new energy, and biomedicine sectors to mitigate risks [8].

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the registration certificate of L-carnitine injection, which is used to treat complications arising from secondary carnitine deficiency in patients with chronic kidney failure undergoing long-term hemodialysis [1] Group 1 - The L-carnitine injection is indicated for symptoms such as cardiomyopathy, skeletal muscle disease, arrhythmia, hyperlipidemia, low blood pressure, and muscle cramps during dialysis [1] - The approval of L-carnitine injection enriches the company's product line and enhances its market competitiveness [1] - The product is classified as a Category 4 chemical drug, which is considered equivalent to passing the consistency evaluation according to national policies [1]

浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的左卡尼汀注射液的《药品注册证书》， 现将相关情况公告如下： 一、药品的基本情况 药品名称：左卡尼汀注射液 剂型：注射剂 规格：5ml:1g 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2026-002 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 左卡尼汀注射液用于慢性肾衰长期血透病人因继发性肉碱缺乏产生的一系列 并发症状，临床表现如心肌病、骨骼肌病、心律失常、高脂血症，以及低血压和透 析中肌痉挛等。左卡尼 ...

Core Viewpoint - Huahai Pharmaceutical has received approval from the National Medical Products Administration for the registration of L-carnitine injection, which is intended for patients with chronic renal failure undergoing long-term hemodialysis and suffering from secondary carnitine deficiency-related complications [1] Group 1 - The L-carnitine injection is used to address complications such as cardiomyopathy, skeletal muscle disease, arrhythmias, hyperlipidemia, low blood pressure, and muscle cramps during dialysis [1] - The company has invested approximately 4.69 million yuan in the research and development of the L-carnitine injection project [1]

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the registration certificate of L-carnitine injection, which is used for complications arising from secondary carnitine deficiency in patients with chronic renal failure undergoing long-term hemodialysis [1] Group 1 - The L-carnitine injection is indicated for symptoms such as cardiomyopathy, skeletal myopathy, arrhythmia, hyperlipidemia, low blood pressure, and muscle cramps during dialysis [1] - The approval of L-carnitine injection enriches the company's product line and enhances its market competitiveness [1] - The product is classified as a chemical drug of category 4, which is considered equivalent to passing the consistency evaluation according to national policies [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of L-Carnitine Injection, which is intended for treating complications arising from secondary carnitine deficiency in patients with chronic renal failure undergoing long-term hemodialysis [1] Group 1 - The L-Carnitine Injection is classified as a Class 4 chemical drug, which is equivalent to passing the consistency evaluation, enhancing the company's market competitiveness [1] - The company has invested approximately 4.69 million yuan in the research and development of the L-Carnitine Injection project [1] - The projected domestic market sales for L-Carnitine Injection are estimated to reach approximately 508 million yuan in the first half of 2025 [1]

Group 1 - The core viewpoint of the news is that Zhejiang Huahai Pharmaceutical Co., Ltd. has undergone a site inspection by its sponsor, Zheshang Securities, which found that the company is operating well in terms of corporate governance, internal control, and compliance with regulations [1][12] Group 2 - The site inspection was conducted on December 30, 2025, and involved reviewing the company's governance documents, internal control systems, and financial practices [3][4] - The inspection confirmed that the company has a complete governance structure and that its internal control systems are effectively implemented [2][4] - The company has maintained independence from its controlling shareholders and has not engaged in any improper transactions with related parties [4][5] Group 3 - The use of raised funds was found to be compliant, with all funds stored in designated accounts and no evidence of misuse or unauthorized changes in fund allocation [5][6] - There were no violations related to external guarantees, related transactions, or significant external investments during the inspection period [5][6] Group 4 - The company's operational status remains stable, with no significant adverse changes in its business model or structure [6][12] - The company is advised to continue enhancing its corporate governance and risk management practices to ensure accurate and complete information disclosure [8]